SCHEMBL6645860

SCHEMBL6645860

Cc1ccc(C(=O)Nc2ccc(NCCc3ccccn3)nc2)c(N2CCCCC2)n1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 4/20 0.48
ALDH1A1 P00352 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
KIF18A Q8NI77 4/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 2/20 0.41
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PKM P14618 1/20 0.40
HTT P42858 1/20 0.40
KLF5 Q13887 1/20 0.40
CYP1A2 P05177 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6649236 0.92 OGA (0.49) SCN10AALDH1A1KIF18ANPC1RAB9A
SCHEMBL6647784 0.90 ALDH1A1 (0.52) SCN10AALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL6649491 0.89 SCN10A (0.50) SCN10AALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL6647575 0.83 NPC1 (0.45) ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL6645448 0.82 L3MBTL1 (0.55) SCN10AALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL6644190 0.82 OGA (0.52) SCN10AALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL6644850 0.82 PTPN11 (0.42) SCN10AALDH1A1L3MBTL1KIF18ANPC1
SCHEMBL6643983 0.82 PDE4B (0.49) SCN10AALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL6648292 0.79 SCN10A (0.47) SCN10AALDH1A1L3MBTL1KIF18ANPC1
SCHEMBL6646240 0.79 RAB9A (0.39) SCN10AALDH1A1L3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR SCN10A 1201/4885ALDH1A1 2174/4885L3MBTL1 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.